{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:11:37Z","timestamp":1780636297037,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinthera.2024.09.014","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T20:42:22Z","timestamp":1727728942000},"page":"1082-1085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Toxic Epidermal Necrolysis Observed in a Patient With the HLA-B*1502 Treated With Levofloxacin"],"prefix":"10.1016","volume":"46","author":[{"given":"Xiufang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5141-4655","authenticated-orcid":false,"given":"Juyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.014_bib0001","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0002","doi-asserted-by":"crossref","first-page":"612","DOI":"10.12688\/f1000research.24748.1","article-title":"Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Hasegawa","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0003","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1081-1206(10)60521-2","article-title":"Toxic epidermal necrolysis induced by levofloxacin","volume":"102","author":"Davila","year":"2009","journal-title":"Annals Allergy Asthma Immunol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0004","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaci.2015.05.050","article-title":"Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response","volume":"136","author":"White","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0006","doi-asserted-by":"crossref","first-page":"DES183","DOI":"10.1167\/iovs.17-23537","article-title":"Results of detailed investigations into Stevens-Johnson syndrome with severe ocular complications","volume":"59","author":"Ueta","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0007","first-page":"FC01","article-title":"Antecedent drug exposure aetiology and management protocols in Steven-Johnson syndrome and toxic epidermal necrolysis, a hospital based prospective study","volume":"10","author":"Farhat","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0008","doi-asserted-by":"crossref","first-page":"10589","DOI":"10.1038\/s41598-020-67610-5","article-title":"HLA genotypes and cold medicine-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis","volume":"10","author":"Tangamornsuksan","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0009","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1345\/aph.1E613","article-title":"Levofloxacin-induced fatal toxic epidermal necrolysis","volume":"39","author":"Islam","year":"2005","journal-title":"Annals Pharmacother"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0010","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1592\/phco.22.9.789.34074","article-title":"Levofloxacin-induced toxic epidermal necrolysis in an elderly patient","volume":"22","author":"Digwood-Lettieri","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0011","doi-asserted-by":"crossref","first-page":"660","DOI":"10.47102\/annals-acadmedsg.V39N8p660","article-title":"Levofloxacin-induced toxic epidermal necrolysis treated with intravenous immunoglobulin","volume":"39","author":"Teo","year":"2010","journal-title":"Annals Acad Med Singapore"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0012","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1574886311666160427104417","article-title":"A case report of antitubercular drugs induced exanthematous reaction complicated by acute onset levofloxacin induced toxic epidermal necrolysis (TEN)","volume":"13","author":"Gajjar","year":"2018","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0013","doi-asserted-by":"crossref","first-page":"666","DOI":"10.12659\/AJCR.899823","article-title":"Levofloxacin induced toxic epidermal necrolysis: successful therapy with omalizumab (Anti-IgE) and pulse prednisolone","volume":"17","author":"Uzun","year":"2016","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4103\/0253-7613.121380","article-title":"Levofloxacin and furazolidone induced toxic epidermal necrosis","volume":"45","author":"Varma","year":"2013","journal-title":"Ind J Pharmacol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0015","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1345\/aph.1E587","article-title":"Generalized seizure and toxic epidermal necrolysis following levofloxacin exposure","volume":"39","author":"Christie","year":"2005","journal-title":"Annals Pharmacother"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0016","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-018-2569-3","article-title":"Incidence of Stevens-Johnson syndrome\/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study","volume":"75","author":"Rodriguez-Martin","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0017","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/pds.4622","article-title":"Active surveillance of severe cutaneous adverse reactions: a case-population approach using a registry and a health care database","volume":"27","author":"Rodriguez-Martin","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Therap"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0019","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and comparison of performance of ABCD-10 and SCORTEN in prognostication of epidermal necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0020","doi-asserted-by":"crossref","first-page":"h4848","DOI":"10.1136\/bmj.h4848","article-title":"Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study","volume":"351","author":"Ko","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0021","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13075-020-02273-1","article-title":"Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study","volume":"22","author":"Do","year":"2020","journal-title":"Arthr Res Ther"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0022","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.bjps.2016.01.034","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"69","author":"Creamer","year":"2016","journal-title":"J Plastic Reconstruct Aesthet Surg"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0023","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0024","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ophtha.2006.10.029","article-title":"New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome","volume":"114","author":"Sotozono","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ophtha.2008.12.048","article-title":"Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications","volume":"116","author":"Sotozono","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0026","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0027","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.644871","article-title":"Associations between Stevens-Johnson syndrome and infection: overview of pharmacoepidemiological studies","volume":"8","author":"Imatoh","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0029","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/0128071-200809060-00008","article-title":"Mycoplasma pneumoniae-associated mucositis with minimal skin manifestations","volume":"9","author":"Figueira-Coelho","year":"2008","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fmicb.2016.00023","article-title":"Classification of extrapulmonary manifestations due to mycoplasma pneumoniae infection on the basis of possible pathogenesis","volume":"7","author":"Narita","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0031","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF03345295","article-title":"Fatal toxic epidermal necrolysis in autoimmune polyglandular syndrome Type I","volume":"27","author":"Porzionato","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.clinthera.2024.09.014_bib0032","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-200326020-00004","article-title":"Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three Italian regions","volume":"26","author":"Leone","year":"2003","journal-title":"Drug safety"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T06:23:56Z","timestamp":1734071036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0149291824002741"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxic Epidermal Necrolysis Observed in a Patient With the HLA-B*1502 Treated With Levofloxacin","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}